

Class A: ETAHX | Class C: ETCHX | Class I: ETIHX | Class N: ETNHX

HEALTHCARE & LIFE SCIENCES FUND AT A GLANCE

Manager: Dr. Finny Kuruvilla

Fund Objective: Seeks to provide long-term capital appreciation

About the Fund: A diversified mutual fund representing our "best ideas" for long-term capital appreciation in the healthcare and life sciences sectors (≥80%). Concentrates investments in the drug-related industries (≥25%). May invest in illiquid securities (≤15%).

Benchmark: S&P 500 Total Return Index

Secondary Benchmark: S&P Biotechnology Select Industry Index

Morningstar Category: Health

Lipper Category: Health/Biotech

Net Assets: \$919 million

Inception Date: December 27, 2012

Healthcare and life sciences companies include those companies that derive or are expected to derive 50% or more of their revenue from healthcare and life science products and services including, but not limited to, biotechnology, pharmaceuticals, diagnostics, life science tools, medical devices, healthcare information technology, healthcare services, synthetic biology, agricultural and environmental management, and pharmaceutical manufacturing products and services. These companies include smaller development-stage companies.

REVIEW

The Eventide Healthcare & Life Sciences Fund Class N posted a 9.63% total return for Q3 2018, compared with the S&P Biotechnology Select Industry Index of 0.75% and the S&P 500 Total Return Index of 7.71%.

CONTRIBUTORS

In the third quarter of 2018, the largest positive contributors to performance were AVRO, KALV, SRPT, ANAB, and MYOK. Avro had a strong IPO and follow through price action as investors were encouraged by early clinical data on their gene therapy for Fabry's Disease. Kalvista shares advanced on updated data on its oral plasma kallikrein inhibitor program for Hereditary Angioedema (HAE). Sarepta gained as they advanced their gene therapy assets for Muscular Dystrophy. Anaptysbio investors changed their focus from peanut allergy to their advancing Asthma biologic candidate. Myokardia moved higher through the period on increased awareness and confidence in their targeted medicines for cardiovascular disease.

Top Five Contributors¹

Q3 2018

Company	Ticker	Industry	Average Weight	Contribution	Total Return
Avrobio	AVRO	Biotechnology	4.07	2.68	81.62
Kalvista Pharmaceuticals	KALV	Biotechnology	1.49	1.64	172.29
Sarepta Therapeutics	SRPT	Biotechnology	4.98	1.13	22.19
Anaptysbio	ANAB	Biotechnology	1.76	0.70	40.44
Myokardia Inc	MYOK	Biotechnology	2.24	0.65	31.32

DETRACTORS

In the third quarter of 2018, the largest detractors to performance were COLL, SAGE, MDGL, GBT, and EIDX. Collegium shares were pressured during the quarter amid slowing prescription metrics for its lead asset, an abuse deterrent pain formulation. Sage shares drifted lower in a quarter without data or catalysts. Madrigal came under pressure in light of strong data from a competitor in the nonalcoholic steatohepatitis (NASH) space. Global Blood Therapeutics declined in the second half of the quarter as investors became concerned with risks for the company's unique accelerated regulatory path for its Sickle Cell Disease program. Eidos Therapeutics dropped significantly following competitor data for its lead asset in the transthyretin (TTR) amyloidosis (ATTR).

Top Five Detractors¹

Q3 2018

Company	Ticker	Industry	Average Weight	Contribution	Total Return
Collegium Pharmaceutical Inc	COLL	Biotechnology	2.00	-1.12	-38.20
Sage Therapeutics Inc.	SAGE	Biotechnology	3.34	-0.39	-9.76
Madrigal Pharmaceuticals Inc.	MDGL	Biotechnology	1.30	-0.37	-23.44
Global Blood Therapeutics Inc.	GBT	Biotechnology	0.49	-0.32	-22.92
Eidos Therapeutics Inc.	EIDX	Biotechnology	0.48	-0.31	-31.61

MACRO COMMENTARY AND OUTLOOK

Health care, in particular biotech, has continued its strong run of IPOs and funding for SMID-cap companies. This bodes positive for the space in the long-run as there are more investment opportunities, with enhanced capitalization. Positive data in diseases like muscular dystrophy, autoimmunity, and nonalcoholic steatohepatitis (NASH) have increased the fundamental value of the space. On the negative side, larger companies continue to suffer from compressed multiples as investors remain unconvinced about their long-term earning potential, given various patent cliffs. We believe that this will continue to make SMID-cap interesting, given the increased likelihood that larger companies will be forced to acquire novel assets to replenish their pipeline. The principal long-term risk of biotech remains political—that is, the likelihood of government pricing reducing long-term investor returns. We believe that the midterm elections are low risks to the positive trajectory on which biotechnology remains.

Class A: ETAHX | Class C: ETCHX | Class I: ETIHX | Class N: ETNHX

Fund Returns ²		30 Sep 2018			
<i>Eventide Healthcare & Life Sciences Fund</i>	YTD	1-year	3-year ⁴	5-year ⁴	Since Inception ⁴
Class N	31.85%	38.15%	23.64%	19.79%	26.53%
Class A without load	31.75%	38.02%	23.57%	19.72%	26.44%
Class A with 5.75% load	24.18%	30.07%	21.15%	18.31%	25.15%
Class C	31.04%	37.02%	22.66%	18.84%	25.52%
Class I	32.03%	38.39%	23.87%	20.02%	26.77%
<i>Benchmarks</i>					
S&P 500 Total Return Index ³	10.56%	17.91%	17.31%	13.95%	15.69%
S&P Biotechnology Select Industry TR ³	13.17%	11.09%	15.75%	17.57%	23.17%

Performance is historical and does not guarantee future results. Investment return and principal value will fluctuate with changing market conditions so that when redeemed, shares may be worth more or less than their original cost. Current performance may be lower or higher than the data quoted. Investors cannot directly invest in an index and unmanaged index returns do not reflect any fees, expenses or sales charges. To obtain the most recent month-end performance information and a current Eventide Healthcare & Life Sciences Fund prospectus please call the fund, toll free at 1-877-771-EVEN (3836).

Eventide Healthcare & Life Sciences Fund expenses: Class A, Total Expenses 1.60%; Class C, Total Expenses 2.35%; Class I, Total Expenses 1.35%; Class N, Total Expenses 1.55%.

1. Source: Bloomberg PORT Attribution Report

2. The returns shown do not reflect the deduction of taxes that a shareholder would pay on fund distributions or on the redemption of fund shares. Because of ongoing market volatility, fund performance may be subject to substantial short-term changes.

3. Performance figures for periods greater than 1 year are annualized. Annualized since inception returns assume an inception date of December 27, 2012.

4. The S&P 500 is an index created by Standard & Poor's of American stocks with the largest market capitalization. It is not an investment product available for purchase. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The volatility of the indices may be materially different than that of the fund, and investors should not expect the fund to achieve the same results as the indices listed.

The opinions expressed herein are those of fund's portfolio management team as of 30 September 2018, and subject to change. There is no guarantee that the outlook opinions will come to pass. Specific companies mentioned are for performance attribution informational purposes only and should not be construed as buy or sell advice. Reliance upon the views expressed herein is at the sole discretion of the reader.

Mutual Funds involve risk including the possible loss of principal. Past performance does not guarantee future results. The Fund can invest in smaller-sized companies which may experience higher failure rates than larger companies and normally have a lower trading volume than larger companies. The Fund's ethical values screening criteria could cause it to under perform similar funds that do not have such screening criteria. The Fund can have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the U.S. Food and Drug Administration. The Fund can have risk related to option investing. There are special risks associated with investments in foreign companies including exposure to currency fluctuations, less efficient trading markets, political instability and differing auditing and legal standards. The Fund can invest in private companies. Private investments include various risks including but not limited to lack of liquidity, capital commitment risk, and valuation risk. Private companies may not be financially profitable and have uncertain futures, subjecting them to additional risks. Because of ongoing market volatility, Fund performance may be subject to substantial short-term changes.

Investors should consider the Fund's objectives, risks, charges and expenses carefully before investing or sending money. This and other important information about the Eventide Healthcare & Life Sciences Fund can be found in the Fund's prospectus, which can be obtained at www.eventidefunds.com or by calling 877-771-EVEN (3836). Please read the prospectus carefully before investing. The Fund is distributed by Northern Lights Distributors, Member FINRA/SIPC, which is not affiliated with Eventide Asset Management, LLC.